News

Gencure, a subsidiary of BioBridge Global, offers a variety of ways for you to stay connected with us. You can read our latest press releases or the Annual Reports. Visit the Events Page to find out what’s coming up. You can watch a video clip from a newscast, view past events in the Photo Gallery or read industry news. For the social media enthusiast, the BioBridge family is known as “Connect for Life,” and can be found on FacebookTwitterLinkedIn and YouTube. Also, visit our blog here.

Media is welcome to contact the Corporate Communications Department for more information. We offer:

  • 
Interviews with experts in their respective medical fields
  • Interviews with Life Links - community members touched by the services of BioBridge Global
  • Informative tours of the facility

Please contact:
Corporate Communications
Phone: (210) 731-5519
Mobile: (210) 296-9026
Email: crd@biobridgeglobal.org

Recent News Articles

May 2, 2014

SAN ANTONIO, Texas, May 1, 2014 (GLOBE NEWSWIRE) -- Genetics Policy Institute (GPI) announced four prestigious "Organizing Partners" of the 10th annual World Stem Cell Summit. The 2014 Summit will be held December 3-5, 2014, at the San Antonio Marriott Rivercenter in San Antonio, Texas.

GPI, The University of Texas Health Science Center at San Antonio, Mayo Clinic, Kyoto University Institute for Integrated Cell-Material Sciences (iCeMS) and BioBridge Global will organize the 10th annual meeting of the global stem cell community, shaping the next year of progress in regenerative medicine. The annual event assembles the most prominent figures in the field to share research, build collaborations and find solutions to funding and commercialization challenges.

September 28, 2013

You will find the same helpful information as our previous site, but with enhanced features for upcoming events, social media and news as well as easier access to important information.

The GenCure website covers marrow donor services, tissue services, peripheral blood stem cell collection, and cord blood cellular therapy programs.

If you look at the very top of the screen, you will see links to BioBridge Global. BioBridge Global (BBG) is a non-profit company that oversees and supports GenCure, QualTex Laboratories, the South Texas Blood & Tissue Center, and The Blood and Tissue Center Foundation. Its mission is to bridge critical medical needs with innovative solutions. The black menu bar has links to information such as About BioBridge, Get Involved, Employment, and Contact Information. There is also a convenient drop down menu to connect to any subsidiary of the BBG network. 

Research Study Can Help Impact the Blood Supply
September 27, 2013
SAN ANTONIO – BioBridge Global has established an investigational study agreement with ExThera Medical to serve as a testing site for a new Seraph® Microbind® technology. The new filter device will be tested for its ability to remove bacteria and viruses from human banked blood and blood products using ExThera’s broad-spectrum biomimetic sorption hemoperfusion technology.
 
BioBridge Global (BBG) is a nonprofit company that oversees and supports the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure, and The Blood and Tissue Center Foundation. BioBridge Global’s mission is to bridge critical medical needs with innovative solutions. BBG and its affiliates have established research relationships with Scripps Research Institute, StemBioSys, Inc., University of Texas Health Science Center, Saneron CCEL Therapeutics, Inc. and Dendreon.
 
June 27, 2013
The organization’s board created the holding company in 2012 to oversee and support its main business units, which include STBTC, QualTex Laboratories and GenCure, as well as the Blood and Tissue Center Foundation.
October 23, 2012

SAN ANTONIO - The South Texas Blood & Tissue Center (STBTC), through its GenCure affiliate, has established a research collaboration agreement with San Antonio-based StemBioSys, Inc. to provide mononuclear cells from clinical grade human umbilical cord blood (hUCB) to StemBioSys for research and development use.

StemBioSys will utilize the hUCB stem cells to further evaluate the use of its patented extracellular matrix technology for the isolation and expansion of a rare subset of stem cells found in hUCB. Previous research performed by StemBioSys co-founder Dr. Xiao-Dong Chen has indicated that these cells contain properties indicative of a primordial stem cell population with a broad range of potential use in stem cell research, drug development and therapeutic applications.

Pages